ORIGINAL INVESTIGATION

The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization

Nikolaos P. E. Kadoglou1,2*, Emmanouil Korakas3, Christos Karkos4, Eirini Maratou3, Ioannis Kanonidis2, Panagiotis Plotas5, Nikolaos Papanas6, Paraskevi Moutsatsou7, Ignatios Ikonomidis8 and Vaia Lambadiari3

Abstract

Background: RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptomatic peripheral artery disease (PAD) and their possible prognostic role in major adverse cardiovascular events (MACE).

Methods: We enrolled 168 consecutive patients with symptomatic, established PAD, requiring revascularization by endovascular means of any or both of their lower limbs. 88 age- and sex-matched subjects with less than 2 classical cardiovascular risk factors served as controls. Clinical parameters, glycemic and lipid profile, RBP4 and adiponectin levels were assayed. The occurrence of MACE was recorded during the 6-month follow-up and patients were assigned to MACE and non-MACE subgroups.

Results: The presence of symptomatic PAD was significantly correlated with age, diabetes, hsCRP, RBP4 and low adiponectin levels (p < 0.05). After adjustment for age, RBP4 (β = 0.498, p < 0.001), and adiponectin (β = -0.288, p < 0.001) levels remained as independent predictors of PAD presence in the whole study cohort. At baseline, MACE subgroup appeared with higher RBP-4 and hsCRP serum levels than non-MACE subgroup (p < 0.001), but no differences were detected for adiponectin (p = 0.758). Serum RBP4 levels remained independent predictor of MACE (β = 0.455, p < 0.001) after adjustment for traditional cardiovascular risk factors.

Conclusions: High RBP4 and low adiponectin serum levels are independently associated with PAD presence. In addition, RBP4 is an independent predictor of MACE incidence in symptomatic PAD patients.

Keywords: RBP4, Adiponectin, Peripheral artery disease, MACE, Inflammation

Introduction

Peripheral artery disease (PAD) is a manifestation and a cardinal complication of systemic atherosclerosis and is characterized by progressive stenosis of the peripheral arteries [1]. Apart from the obvious reduced functional capacity, PAD patients experience high rates of cardiovascular (CVD) morbidity and mortality, especially those with chronic, low-grade inflammation, such as diabetes mellitus and obesity [2]. Revascularization of lower-limb arteries has been associated with better long-term survival and quality of life when the patency of the arteries is maintained [3]. However, the restenosis rate and the post-intervention occurrence of major
adverse cardiovascular events (MACE) is still high despite the advances in revascularization techniques and the optimal pharmaceutical therapy [4]. Traditional atherosclerotic factors such as the ankle-brachial index (ABI) have not been proven efficient to identify the PAD patients at greatest risk for MACE. Limited data indicate that inflammatory biomarkers may predict the clinical outcomes of endovascular intervention in PAD [5]. However, more studies are required to establish the prognostic role of novel biomarkers in PAD patients, candidates for revascularization [6].

In recent decades, adipose tissue has been recognized as an active secretory organ through the production of various adipokines, involved in inflammation, insulin resistance and atherosclerosis processes [7]. Retinol-Binding Protein-4 (RBP4) is a relatively novel adipokine [8] which is primarily produced in the liver and in the adipose tissue to a lesser extent, and it is the main transport protein for retinol (vitamin A) in the bloodstream [9]. RBP4 levels are elevated in adiposity and shown positive association with traditional atherosclerotic factors such as dyslipidemia and insulin resistance [10, 11]. Its mediating mechanisms include the proliferation of vascular smooth muscle cells (VSMCs), the increased production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukins 1β,2,8,10 (IL-1β, IL-2, IL-8, IL-10) and adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1), and the impairment of glucose metabolism and adipose tissue function [9]. Nevertheless, its association with adverse cardiovascular outcomes has not been a consistent, with data in PAD patients being even more scarce [12].

Adiponectin is a 244-aminoacid long polypeptide, almost exclusively produced by adipocytes [13]. Contrary to the other adipokines, its levels are lower in obesity, and it exerts an anti-inflammatory, insulin-sensitizing and anti-atherogenic effect. Although initial in vitro studies had firmly established the cardio-protective role of adiponectin, human studies have been contradictory [14]. Low levels of adiponectin have been associated with higher incidence of PAD [15, 16], along with an increased risk of MACE in patients with symptomatic PAD [17]. On the other hand, large-scale studies and meta-analyses have documented a positive or null association between adiponectin levels and cardiac or renal disease, along with increased rates of MACE in patients with PAD [18–21]. The reasons for these discrepancies, known as “adiponectin paradox”, are yet to be elucidated.

The aim of the present study was to evaluate the relationship of serum adiponectin and RBP4 not only with PAD, but with MACE during 6-month follow-up of patients with symptomatic PAD undergoing lower limb endovascular revascularization.

Methods
Participants
In the present prospective, non-randomized study, we enrolled 168 consecutive patients with symptomatic, established peripheral artery disease (PAD) requiring revascularization by endovascular means (balloon angioplasty and/or stent placement) of any or both of their lower limbs. The diagnosis of severe PAD was based on ankle-brachial index (ABI < 0.80), peripheral artery stenosis > 50% documented by duplex ultrasound and angiography and symptoms of intermittent claudication, rest pain and/or skin lesions according to the TASC guidelines [22]. Ineligible patients were considered those with concurrent conditions/diseases interfering with the expression of inflammatory mediators, like active infection, wet gangrene, severe kidney or liver impairment, morbid obesity, cancer, cardiovascular ischemic events within the recent 1 month, any major surgery or severe trauma over the last 3 months and chronic inflammatory or autoimmune diseases. We also excluded patients with PAD planned for open surgery or hybrid (open surgery combined with endovascular revascularization) due to anatomical reasons. The study was approved by the local Research and Ethics committee (IRB Nr 806/23.09.2013) and patients provided a written informed consent prior to their participation.

Among subjects visiting our outpatient clinics for check-up, we identified age- and sex-matched subjects with less than 2 classical cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, current smoking, family history of premature CAD) to participate in our research. All those individuals were free from any chronic cardiovascular disease (neither coronary artery disease—CAD nor PAD) based on test of myocardial ischemia and ultrasound of peripheral arteries within the last 2 years. Finally, 88 individuals agreed to participate to the present study and served as control group.

Study design
At baseline, all participants underwent clinical examination, blood sampling and ultrasound examination of both lower-limb arteries. Besides this, all PAD patients also underwent lower-limb angiography as a part of plan procedure and they were on optimal medical therapy, including statins (LDL target < 100 mg/dl) and antiplatelet therapy prior to intervention. All percutaneous revascularization procedures were performed as previously described [23]. Iliac lesions were predominantly treated with stenting, while stent employment was provisional for superficial femoral artery, popliteal and infrapopliteal lesions.

Post-procedure, patients were put on dual antiplatelet therapy with clopidogrel (75 mg) and acetyl
salicylic acid (100 mg) for 6 months. Written dietary and exercise recommendations were provided to all participants at baseline, but without further monitoring. At the end of follow-up period (6 months), clinical examination, blood sampling and lower-limb ultrasound were repeated only in PAD patients. In case of intermittent claudication relapse accompanied by ABI deterioration and ultrasound indications of restenosis (degree of stenosis ≥ 50%), the angiographic examination was repeated. Re-revascularization was conducted in those symptomatic patients with angiographically stenosis ≥ 50% found either in stents or at lesion sites of previously balloon angioplasty. The occurrence of major cardiovascular events (MACE) including acute coronary events and peripheral artery stenosis requiring re-revascularization (either endovascular or open surgery) were recorded during the 6-month follow-up based on medical records. All cases were peer-reviewed by a multi-disciplinary team (vascular surgeons and cardiologists) which decided based on medical records whether they fulfilled the MACE criteria or not. Regarding MACE incidence, PAD patients were further divided into MACE and non-MACE subgroups for analysis purposes. It is quite common in clinical practice for PAD patients to experience MACE shortly after the revascularization procedure. Moreover, we focused on the pro-inflammatory burden of our patients to get firm conclusion about the contribution of inflammatory mediators to MACE. Thereby, we considered the 6-months period long enough to record an adequate number of MACEs, associated with adipokines.

Clinical examination
Anthropometrical parameters, like body-mass index (BMI) and waist-to-hip ratio (WHR) were calculated in all participants by a single operator. Blood pressure was measured twice, after keeping participants at a sitting position for 15 min. There was a 5-min interval between the two measurements and the mean value was estimated. Moreover, past and current medical history including medications and co-morbidities, lifestyle habits (smoking, physical activity) were documented through structure questionnaire from our previous published work [24].

Initially the diagnosis of PAD was set using the ankle-brachial index ≤ 0.9. Thereafter, ultrasonographically- or angiographically-demonstrated stenosis (≥ 75 of the cross-sectional area) was demonstrated on ultrasound or angiogram of the iliac arteries or below (Philips CX 50 ultrasound machine, Bothell, WA 98021, USA).

Blood assays
Fasting blood samples were obtained after overnight fasting. Glycemic and lipid parameters were all assayed in an automatic enzymatic analyzer (Olympus AU560, Hamburg, Germany). The glycated haemoglobin (HbA1c) was determined by high-performance liquid chromatography (Menarini Diagnostics, Florence, Italy) only in diabetic patients. A quantity of blood samples was collected and after a centrifugation at 2500 rpm for 10 min frozen serum samples were stored (−80°C) until analysis in the same assay. Serum adiponectin, and RBP-4 were assayed using quantikine enzyme immunoassay commercially available kits (Phoenix Pharmaceuticals, Belmont, CA, USA and Immunodiagnostik AG, Bensheim, Germany, respectively). The intra-assay CV for RBP-4 and adiponectin were 9.7% and the inter-assay CV were 5% and %, respectively. The high-sensitivity C-Reactive Protein (hsCRP) levels were measured with latex-enhanced immunonephelometry (Dade Behring, Marburg, Germany).

Statistical analysis
Normality of distribution was assessed with Kolmogorov-Smirnov test. Results of normally distributed continuous variables were expressed as the mean value ± SD. Continuous and categorical variables were compared using the student’s t-test and chi-square test, respectively. A two-tailed p value < 0.05 was considered to be statistically significant. Pearson’s correlation coefficient was calculated to determine the strength of the association of PAD presence with continuous variables. After univariate analysis, variables showing a significant correlation with PAD entered a logistic multiple regression analysis to check for independent associations. The computer software package SPSS (version 25.0; SPSS Inc, Chicago, IL, USA) was used for statistical analysis.

Results
Baseline characteristics
At baseline, we observed significant differences between PAD patients and healthy controls regarding blood pressure, smoking rates, HDL, hsCRP, RBP4 and adiponectin levels (p < 0.05). The high prescription rate of statins in PAD group may explain the absence of difference in most lipid parameters between those two groups. Nevertheless, the majority of PAD patients did not achieve the LDL target. After comparison of statin-treated and statin-free participants we observed non-significant difference in their serum levels of both RBP4 and adiponectin (data not shown). We also checked the serum levels in non-diabetic participants between PAD and control groups. Serum levels of adiponectin
remained significantly lower in non-diabetic PAD patients than their non-diabetic controls (8.12 ± 2.97 vs. 11.88 ± 3.05 mg/L; p = 0.004). Non-significant difference we observed for RBP4 between non-diabetic subgroups. The clinical and laboratory characteristics of PAD and control groups are presented in Table 1.

Table 1 Clinical and laboratory characteristics of patients with peripheral artery disease (PAD group) and controls (CO group) at baseline

|                      | PAD group (n=168) | CO group (n=74) | P value |
|----------------------|------------------|----------------|---------|
| Age (y)              | 76 ±11           | 70 ±10         | 0.223   |
| Males, n (%)         | 141 (83.9)       | 60 (81)        | 0.929   |
| Smoking, n (%)       | 43 (25.6)        | 13 (17.6)      | <0.001  |
| Hypertension, n (%)  | 125 (74.4)       | 13 (17.6)      | <0.001  |
| Dyslipidemia, n (%)  | 162 (96.4)       | 35 (47.3)      | <0.001  |
| Statins, n (%)       | 160 (95.2)       | 19 (25.7)      | <0.001  |
| ABI                  | 0.48 (0.09)      | 1.1 (0.1)      | <0.001  |
| Diabetes, n (%)      | 68 (40.3)        | 7 (9.5)        | <0.001  |
| BMI (kg/m²)          | 27.96 ± 3.32     | 26.9 ± 3.42    | 0.212   |
| SBP (mmHg)           | 139 ± 21         | 125 ± 12       | <0.001  |
| DBP (mmHg)           | 85 ± 9           | 78 ± 8         | 0.405   |
| Creatinine (mg/dl)   | 1.61 ± 0.4       | 1.1 ± 0.3      | 0.112   |
| TChol (mg/dl)        | 183 ± 54         | 162 ± 41       | 0.105   |
| HDL-C (mg/dl)        | 41 ± 8           | 49 ± 13        | 0.013   |
| LDL-C (mg/dl)        | 117 ± 43         | 92 ± 22        | 0.072   |
| TG (mg/dl)           | 122 ± 64         | 106 ± 33       | 0.199   |
| FPG (mg/dl)          | 145 ± 35         | 100 ± 17       | <0.001  |
| HbA1c (%)            | 7.3 ± 1.4        | –              | –       |
| WBC (cells/µL)       | 9,084 ± 2,998    | 6,234 ± 2,109  | <0.001  |
| hsCRP (mg/L)         | 7.64 ± 2.26      | 1.12 ± 0.42    | <0.001  |
| RBP-4 (mg/L)         | 43.3 ± 18.88     | 15.11 ± 4.45   | <0.001  |
| Adiponectin (mg/L)   | 6.53 ± 2.45      | 12.33 ± 2.11   | <0.001  |

Data are expressed as means ± SD, n, number of patients; BMI, body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TChol, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; WBC, white blood cells; hsCRP, high-sensitivity C-Reactive Protein

* HbA1c was measured only in diabetic patients

Table 2 Clinical and laboratory characteristics within peripheral artery disease group at baseline regarding the MACE incidence during follow-up

|                      | MACE subgroup (n=52) | Non-MACE subgroup (n=116) | P value |
|----------------------|----------------------|---------------------------|---------|
| Age (y)              | 79 ±13               | 74 ±10                    | 0.319   |
| Males, n (%)         | 42 (80.8)            | 99 (85.3)                 | 0.902   |
| Smoking, n (%)       | 27 (51.9)            | 16 (13.8)                 | <0.001  |
| Hypertension, n (%)  | 42 (80.8)            | 83 (71.6)                 | 0.248   |
| Dyslipidemia, n (%)  | 50 (96.1)            | 112 (96.6)                | 0.991   |
| Statins, n (%)       | 49 (94.2)            | 111 (95.7)                | 0.887   |
| ABI                  | 0.46 (0.08)          | 0.49 (0.09)               | 0.821   |
| Diabetes, n (%)      | 22 (42.3)            | 46 (39.7)                 | 0.947   |
| BMI (kg/m²)          | 32.22 ± 3.22         | 27.87 ± 3.11              | 0.878   |
| SBP (mmHg)           | 141 ± 23             | 138 ± 22                  | 0.906   |
| DBP (mmHg)           | 85 ± 8               | 85 ± 9                    | 0.998   |
| TChol (mg/dl)        | 196 ± 57             | 177 ± 40                  | 0.255   |
| HDL-C (mg/dl)        | 39 ± 7               | 42 ± 10                   | 0.623   |
| LDL-C (mg/dl)        | 130 ± 43             | 112 ± 22                  | 0.054   |
| TG (mg/dl)           | 136 ± 64             | 115 ± 48                  | 0.136   |
| FPG (mg/dl)          | 151 ± 40             | 142 ± 33                  | 0.888   |
| HbA1c (%)            | 7.5 ± 1.5            | 7.2 ± 1.3                 | 0.659   |
| WBC (cells/µL)       | 12,110 ± 3,356       | 10,479 ± 2,777            | 0.384   |
| hsCRP (mg/L)         | 10.56 ± 2.92         | 6.33 ± 1.85               | <0.001  |
| RBP-4 (mg/L)         | 59.97 ± 21.27        | 35.87 ± 15.22             | <0.001  |
| Adiponectin (mg/L)   | 7.67 ± 2.88          | 7.67 ± 2.88               | 0.758   |

Data are expressed as means ± SD, n, number of patients; BMI, body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TChol, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; WBC, white blood cells; hsCRP, high-sensitivity C-Reactive Protein

* HbA1c was measured only in diabetic patients

MACE vs. non-MACE subgroup
At baseline, MACE subgroup appeared with marginally significant elevation in LDL-C and significantly higher smoking rate, RBP-4 and hsCRP serum levels than non-MACE subgroup (p < 0.001). Those subgroups did not differ at baseline in the rest of variables, including adiponectin (p < 0.001) (Table 2).

Follow-up results
Among them, we did not detect any significant change from baseline to the end of study in all clinical and laboratory parameters, while the pharmaceutical regimens remained unaltered in both subgroups (data not shown). Despite, the endovascular procedure only a slight minority of PAD smokers ceased smoking during the follow-up.

Correlations
In the whole study cohort, the presence of symptomatic PAD was significantly correlated with age, diabetes,

Major adverse cardiovascular events (MACE)
During the 6-months follow-up period, we recorded 69 MACE in 52 PAD patients (MACE subgroup). In particular, 8 PAD patients experienced an acute cardiovascular event (2 of them died) and another 44 PAD patients underwent at least one new revascularization procedure (endovascular or open surgery) due to restenosis, while 2 of them died due to surgical complications. The rest of PAD patients had an uncomplicated post-intervention 6-months period (116 patients: non-MACE subgroup). Therefore, 164 PAD patients completed the study.
hsCRP, RBP4 and low adiponectin levels (p < 0.05). The latter variables entered a multiple logistic regression analysis. After adjustment for age, RBP4 (β = 0.498, p < 0.001), and adiponectin (β = −0.288, p < 0.001) levels remained as independent predictors of PAD presence (R² = 0.422, p < 0.001) (Table 3).

Similarly, we searched for univariate correlations of MACE with other variables within PAD group. Among variables, RBP4, hsCRP and smoking were significantly correlated with MACE (p < 0.05). Multiple logistic regression analysis was performed to estimate the association of MACE incidence with clinical and biochemical variables, after adjustment for traditional cardiovascular risk factors like diabetes, hypertension, dyslipidemia, smoking and male gender. Serum RBP4 levels remained independent predictor of MACE (β = 0.455, p < 0.001). Based on serum RBP4 levels as an independent predictor of MACE incidence, the area under the ROC curve in our PAD patients was 0.740 (95% CI 0.661–0.819) (Fig. 1).

Table 3 Standard multiple regression analysis of PAD presence (dependent variable) and other independent variables within the whole study cohort (PAD patients and controls)

| Variable | β      | 95% CI      | P value |
|---------|--------|-------------|---------|
| RBP4    | 0.498  | 0.328–0.661 | < 0.001 |
| Adiponectin | −0.288 | −0.363–−0.205 | < 0.001 |
| Age     | 0.598  | 0.101–1.098 | 0.469   |
| Diabetes | 0.083  | −0.012–0.178 | 0.664   |
| hsCRP   | 0.606  | 0.198–0.998 | 0.089   |

Discussion

Adipokines have been extensively studied and have been associated with cardiovascular complications. The present prospective study demonstrated higher RBP4 and lower adiponectin serum levels in patients with PAD undergoing endovascular revascularization than age- and sex-matched individuals without cardiovascular disease. During a 6-month, post-procedure follow-up, we demonstrated for first time the independent association of circulating RBP4 levels with MACE incidence in PAD patients.

RBP4 and cardiovascular disease

Although there is a growing number of studies demonstrating the relationship of RBP4 with either coronary [25] or carotid atherosclerosis [26] to our knowledge, no previous studies have focused on patients with PAD. Our study demonstrated a positive association between RBP4 serum levels and the presence of symptomatic PAD in a cohort of PAD patients and PAD-free controls. The most striking finding of our study was the association of baseline RBP4 serum levels with the post-procedure incidence of acute coronary events or peripheral artery restenosis requiring re-revascularization. Raising a prognostic factor in PAD patients undergoing endovascular revascularization is of great clinical importance, regarding the high occurrence of restenosis and the frequent adverse cardiac events among those patients. The prognostic power of RBP4 has been supported in other populations at high cardiovascular risk like those with chronic heart failure (CHF) [27] and chronic kidney disease (CKD) [28]. Sun et al. [29] showed that full-length and total RBP4 were significant risk factors for the occurrence of coronary artery disease (CAD) among 468 women in the Nurses’ Health Study cohort, especially in the first 8 years of follow-up. On the contrary, other studies have failed to demonstrate the role of RBP4 as a predictor of ischemic stroke [30], or CAD [31]. Surprisingly, Patterson et al. [32] showed that higher RBP4 levels were associated with reduced non-CVD mortality during an average of 15.4 years follow-up. The reasons behind those discrepancies have not yet been elucidated. RBP4 regulates macrophage foam cell formation and enhances chronic endothelial...
inflammation through the activation of macrophages, mediated through the c-Jun-N-terminal protein kinase (JNK) and Toll-like receptor 4 (TLR-4) pathways, along with the activation of NADPH oxidase and NF-Kb [6, 33]. Furthermore, most but not all studies indicate that RBP4 induces the expression of pro-inflammatory molecules such as IL-1β, IL-2, IL-10, VCAM-1, E-selectin, TNF-α and CRP [12, 34]. In fact, RBP4 has been associated with a number of components of metabolic syndrome such as hypertension and hypertriglyceridemia independently of kidney function, such as in our cohort, while it may adversely affect the metabolic profile by increasing insulin resistance through mechanisms such as increased hepatic gluconeogenesis decreased GLUT4 translocation and impaired insulin signalling in adipose tissue [35]. In contrast, there are other data against the pro-atherogenic, pro-inflammatory effects of RBP4. Takebayashi et al. [11] showed a major role of RBP4 in increased nitric oxide (NO) production via stimulation of the PI3K/Akt/eNOS pathway and inhibition of the insulin-mediated endothelin 1 (ET-1) production, collectively leading to vasodilatation. Therefore, the exact actions of RBP4 in atherosclerosis progression and vascular homeostasis are still warranted. In addition, it has not been clarified which of the holo-RBP4 (bound to retinol, comprising 85% of total RBP4 levels) or apo-RBP4 is the main molecule responsible for the pro-inflammatory, dysmetabolic effects, and whether these actions are mediated through retinol or retinoic acid signaling [36]. A clear cut-off value of RBP4 for cardiovascular diseases has not yet been set [9]. The Western blotting technique is considered as the gold standard, but many ELISA (which do not differentiate between holo- and apo-RBP4) or other enzyme immunoassays have been employed in different cohorts [36]. It becomes thus evident that the lack of standardized and validated methods of quantification of serum RBP4 is a confounding factor for studies comparison. Finally, dietary regimens such as the DASH diet, the Mediterranean diet or high-protein diets have been associated with decreased RBP4 levels [6, 37] and, therefore, diet could have also confounded previous results including ours where the adherence to a health dietary pattern was not evaluated.

**Adiponectin and PAD**

Adiponectin has been more extensively studied in PAD patients than RBP4. In agreement to previous published research, we found lower adiponectin levels within PAD patients and a significant, independent negative association between adiponectin and PAD presence [13, 38]. Iwashima et al. [39] have pointed out a significant association of adiponectin with ABI, implying a relation of adiponectin to disease severity. similarly, in a subgroup within the Health Professionals Follow-up Study consisting of 18,225 men followed-up for 14 years, adiponectin was associated with a 42% lower risk of PAD per SD increase, with only a small attenuation after adjustment for HDL-C, LDL-C, CRP and cystatin C [40].

The mechanisms underlying those favourable vascular effects of adiponectin are related to its various anti-inflammatory, anti-atherogenic properties. Adiponectin inhibits TLR-mediated activation of NFκB and adhesion molecules (VCAM-1, intercellular adhesion molecule-1-ICAM-1), and inhibits the transformation of macrophages into foam cells [11]. In addition, adiponectin exerts antioxidant actions, such as increasing phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) at Ser1177 or decreasing the activation of NADPH-oxidases, together with insulin-sensitizing capacities, by reducing hepatic glucose output and stimulating glucose use and fatty acid oxidation in muscles, through phosphorylation of the insulin receptor and activation of AMP-activated protein kinase [41]. Above all, it diminishes the proliferation of VSMCs, a pivotal mechanism of atherosclerosis progression.

**Adiponectin and MACE: discrepancies and possible explanations**

Despite the inverse relationship between adiponectin and PAD, we failed to demonstrate its association with MACE occurrence. This was not surprising, since research data are controversial regarding the possible prognostic value of adiponectin (positive, negative, neutral). Urbonaviciene et al. [17], have shown that a 1 mg/l increase in adiponectin levels was associated with a 22% decrease of MACE incidence in symptomatic PAD patients, but this effect was limited only to male participants. Dieplinger et al. [42], in a similar cohort to ours, showed a positive association of adiponectin with 5-year mortality in symptomatic PAD patients (RR:1.05 per 1 mg/l increase), with this independent association being lost only after adjustment for NT-proBNP (not measured in our study). In a large-scale prospective study where 4,274 patients with acute ischemic stroke were enrolled, elevated levels of adiponectin were associated with increased risk for MACE within 3 years of follow-up [43], and similar results were shown in patients with metabolic syndrome [44], concomitant hemodialysis [45] or hypertension [46]. In patients with type 2 diabetes, serum adiponectin was not associated with the progression of lower limb vascular calcification [47]. The most recent meta-analysis by Scarale et al. [18] demonstrated adiponectin was associated with an increase of 24% and 28% in pooled hazard ratios for all-cause and cardiovascular
mortality, an effect which applied both to total and high-molecular-weight (HMW) adiponectin. On the opposite side and in agreement with our findings a recent study found no association between adiponectin levels and MACE occurrence in PAD patients undergoing superficial femoral artery (SFA) stenting [48].

The conflicting association between adiponectin and cardiovascular mortality is commonly termed as “the adiponectin paradox”. A possible explanation may lie in adiponectin resistance, characterized by hyperadiponectinemia due to the downregulation of AdipoR1 in insulin-resistant states and at the late stages of chronic diseases, [14]. Moreover, genetic alterations, like a single nucleotide polymorphism rs822354 in the ADIPOQ locus, may lead to increased adiponectin levels associated with cardiovascular mortality [49]. Alternatively, hyperadiponectinemia may not be a true causal factor for adverse events, but rather a compensatory mechanism in chronic inflammatory states, which may be eventually ineffective. Other studies have reported the unforeseen pro-inflammatory action of adiponectin [50]. Hence, the present study gives a potential clue for the role of adiponectin in PAD, but its prognostic value needs further, large-scale studies to be clarified.

We must emphasize the significant modification of classical cardiovascular risk factors in PAD patients prior to endovascular intervention. Unambiguously, the optimal pharmaceutical therapy has limited the influence of several cardiovascular risk factors on clinical outcomes. Thereby, the remarkable difference between PAD and control groups in RBP4 and adiponectin are evident despite the high-prescription rate of cardioprotective medications (e.g. anti-hypertensive), in the former group. Notably, previous studies have failed to demonstrate persistently any significant impact of statins on serum levels of RBP4 [9], while data about adiponectin are mixed. A large meta-analysis showed a significant increase in plasma adiponectin levels after statin therapy, with most statin members, but a deleterious decrease was observed with rosuvastatin [51].

Limitations
The relatively small, patient cohort and the short follow-up are among the most common limitations of our study. Furthermore, it is unfeasible to determine whether RBP4 circulating levels as a stratification biomarker play a causative role on the cardiovascular risk or it is only an epiphenomenon. Another important limitation was that the minority of participants was diabetic, which might have influenced the net results of adipokines. It is possible to hypothesize that the presence of diabetes in all patients would have augmented the differences between subgroups. On the other hand, the majority of patients with classical cardiovascular risk factors (e.g. diabetes, dyslipidemia, hypertension etc.) were already on optimal pharmaceutical therapy. So, we cannot rule out the plausible effects of pharmaceutical agents on adipokines, leading to underestimation of its predictive power. Finally, we did not analyze the time of MACE incidence and thereby we could not perform Kaplan Meier analysis which could have added a time dependent pattern of RBP-4. On the other hand, we grouped PAD patients based on MACE, and thereby we focused entirely on the prognostic value of biomarkers on a relatively short-time follow-up period.

Conclusions
This study revealed that higher RBP4 and lower adiponectin serum levels are independently associated with the presence of symptomatic PAD requiring endovascular revascularization. In addition, it is the first study demonstrating an independent positive association between RBP4 levels and MACE incidence in the post-intervention 6-month follow-up in those patients. On the other hand, no association was demonstrated between adiponectin and MACE in the same group. Thus, RBP4 could present as a novel, cost-effective, non-invasive biomarker which could assist in early risk stratification in patients with PAD undergoing revascularization. It could tailor a more intensive pharmaceutical therapy or even a different interventional approach in PAD patients. The clinical meaning of adiponectin serum levels is still controversial, and thereby may not apply in PAD. The role of those biomarkers as causative factors or bystanders could be verified by further large-scale studies. Such studies will establish the associations of these adipokines with cardiovascular disease and elucidate their true prognostic value regarding disease severity and cardiovascular mortality.

Abbreviations
ABI: Ankle-brachial index; BMI: Body-mass index; CAD: Coronary artery disease; CHF: Chronic heart failure; cIMT: Carotid intima-media thickness; CKD: Chronic kidney disease; CVD: Cardiovascular; DBP: Diastolic blood pressure; eNOS: Endothelial nitric oxide synthase; FBG: fasting plasma glucose; FMD: Flow-mediated vasodilatation; HbA1c: Glycosylated hemoglobin; HDL-C: High-density lipoprotein cholesterol; HfP EF: Heart failure with preserved ejection fraction; HfReF: Heart failure with reduced ejection fraction; HR: Hazard ratio; hsCRP: High-sensitivity C-Reactive Protein; ICAM-1: Intercellular adhesion molecule-1; IL: Interleukin; JNK: c-Jun-N terminal protein kinase; LDL-C: Low-density lipoprotein cholesterol; MACE: Major adverse cardiovascular events; MCP-1: Monocyte chemoattractant protein 1; NFkB: Nuclear factor kappa-B; NP: Natriuretic peptide; PAD: Peripheral artery disease; RBP4: Retinol-Binding Protein-4; RR: Relative risk; SBP: Systolic blood pressure; SFA: Superficial femoral artery; SNP: Single nucleotide polymorphism; T2DM: Type 2 diabetes mellitus; TChol: Total cholesterol; TGs: Triglycerides; TLR-4: Toll-like receptor 4; TNF-α: Tumor necrosis factor-α; VACAM-1: Vascular cell adhesion molecule 1; VLDL: Very-low-density-lipoprotein; VSMCs: Vascular smooth muscle cells; WBCs: White blood cells; WHR: Waist-to-hip ratio.

Acknowledgements
Not applicable.
References

1. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003; 163:884–92.

2. Golomb BA, Dang TT, Ciriq MH. Periperal arterial disease: morbidity and mortality implications. Circulation. 2006;114:688–99.

3. Bunte MC, House JA, Spertus JA, Cohen DJ, Marso SP, Safley DM. Association between health status and long-term mortality after percutaneous revascularization of peripheral arterial disease. Catheter Cardiovasc Interv. 2016;87(6):1149–55.

4. Biscetti F, Nardella E, Rando MM, Cecchini AL, Gasbarrini A, Massetti M, Flex A. Outcomes of lower extremity endovascular revascularization: potential predictors and prevention strategies. Int J Mol Sci. 2021;22(4):2002.

5. Bleda S, De Haro J, Acín F, Varela C, Esparrusi J, López de Maturana I. Inflammation burden predicts long-term outcomes in endovascular therapy in peripheral arterial disease. Ann Vasc Surg. 2013; 27(4):459–66.

6. Frystyk J, Tamnov L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005;48:1911–8.

7. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofiliadias EK, Fotiadis G, Kottas G. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY. Trans Res. 2010;155:238–46.

8. Yang Q, Graham TE, Mody N, Pretiner F, Peroni OD, Zabolotny JM, Kotani K, Quadri L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:56–62.

9. Rychter AM, Skrzypczak-Zielierska M, Zielierska A, Eder P, Souto EB, Zawada A, Ratnapaksa AE, Dobrowolska A, Krela-Kazmierczak I. Is the retinol-binding protein 4 a possible risk factor for cardiovascular diseases in obesity? Int J Mol Sci. 2020;21(15):5229.

10. Wessel H, Saeed A, Heegsma J, Connelly MA, Faber KN, Dullaart RPF. Plasma levels of retinol binding protein 4 relate to large VLDL and small LDL particles in subjects with and without Type 2 diabetes. J Clin Med. 2019;8(11):1792.

11. Takebayashi K, Suetsumu M, Wabakayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007; 92:2712–2719.

12. Zabetian-Targhi F, Mahmoudi MJ, Rezaei N, Mahmoudi M. Retinol binding protein 4 in relation to diet, inflammation, immunity, and cardiovascular diseases. Adv Nutr. 2015;6:748–62.

13. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179–88.

14. Francischiatti EA, Dezonne RS, Pereira CM, de Moraes Martins CJ, Celoria BM, de Oliveira PAC, de Abreu VG. Insights into the controversial aspects of adiponectin in cardiometabolic disorders. Horm Metab Res. 2020;52(10):695–707.

15. Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci 2019; 20:1190.

16. Dieplinger B, Poelz W, Halmayer M, Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med. 2008; 46:830–3.

17. Urbanoviciene G, Frystyk J, Flyvbjerg A, Henneberg EW, Lindholt JS. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. Atherosclerosis. 2010; 210:619–24.

18. Scarale MG, Fontana A, Trischitta V, Copetti M, Menzaghi C. Circulating adiponectin levels are paradoxically associated with mortality rate. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-01501.

19. Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013; 42(4):1029–39.

20. Kanhai DA, Kranendonk ME, Uiterwaal CS, van der Graaf Y, Kappelle LJ, Visseren FL. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev. 2013; 14(7):555–67.

21. Komai H, Shibata R, Juri M, Matsuishi K, Ouchi N, Murohara T. Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease. J Vasc Surg. 2009; 50:95–9.

22. Norgren L, Hiatt WR, Dormandy J, Nehler MR, Harris K, Fowkes FGR. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45:S5-67.

23. Giagtzidis IT, Kadoglou NP, Mantas G, Spouthis A, Papazoglou KO, Karakiolis P. Lipids and CDK. The profile of circulating matrix metalloproteinases in patients undergoing lower limb endovascular interventions for peripheral arterial disease. Ann Vasc Surg. 2017;43:188–96.

24. Kadoglou NP, Styroeras GS, Sporthis A, Gkekas C, Gkastounioti A, Mantas G, Nikiita KS, Karakitos P, Liapis CD. Galectin-3, carotid plaque vulnerability, and potential effects of statin therapy. Eur J Vasc Endovasc Surg. 2015;49(1):4–9.

25. Lambardi V, Kadoglou NP, Stavinos V, Maratou E, Antoniadis A, Kolokathis F, Parissis J, Hatziagelaki E, Iliodromitis EK, Dimitriadis G. Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease. Cardiovasc Diabetol. 2014;21:121.

26. Kadoglou V, Lambardi V, Gkastounioti A, Gkekas C, Giannakopoulos TG, Koulia K, Maratou E, Alepaiki M, Kakisis J, Karakitos P, Nikiita KS, Dimitriadis G, Liapis CD. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability. Atherosclerosis. 2014;235(2):606–12.

27. Li F, Xia K, Li C, Yang T. Retinol-binding protein 4 as a novel risk factor for cardiovascular disease in patients with coronary artery disease and hyperinsulinemia. Am J Med Sci. 2014; 348(6):474–9.
28. Su Y, Huang Y, Jiang Y, Zhu M. The association between serum retinol-binding protein 4 levels and cardiovascular events in patients with chronic kidney disease. Lab Med. 2020;51(S):491–7.

29. Sun Q, Kiemman UA, Shi L, Phillips DA, Kahn BB, Hu FB, Manson JE, Albert CM, Rexrode KM. Plasma retinol-binding protein 4 (RBP4) levels and risk of coronary heart disease: a prospective analysis among women in the nurses’ health study. Circulation. 2013;127(19):1938–47.

30. Rist PM, Jiménez MC, Tworoger SS, Hu FB, Manson JE, Sun Q, Rexrode KM. Plasma retinol-binding protein 4 levels and the risk of ischemic stroke among women. J Stroke Cerebrovasc Dis. 2018;27(1):68–75.

31. Mallat Z, Simon T, Benessiano J, Clément K, Taleb S, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholt SM. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 2009; 94:255–60.

32. Patterson CC, Blankenberg S, Ben YS, Heslop L, Bayer A, Low G, Zeller T, Gallacher J, Young J, Yarnell J. Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). Int J Cardiol. 2015;201:113–8.

33. Liu Y, Zhong Y, Chen H, Wang D, Wang M, Ou JX, Xia M. Retinol-binding protein-dependent cholesterol uptake regulates macrophage foam cell formation and promotes atherosclerosis. Circulation. 2017;135:1339–54.

34. Majerczyk M, Kociela P, Chorząga P, Arabzada H, Dwezarek AJ, Bozentowicz-Wikarek M, Brzozowska A, Zbylska A, Puzianowska-Kuźnicka M, Grodzicki T, Więcek A, Olssonecka-Glinianowicz M, Chudek J. Components of metabolic syndrome in relation to plasma levels of retinol binding protein 4 (RBP4) in a cohort of people aged 65 years and older. J Endocrinol Invest. 2018; 41:1211–1219.

35. Nono Nankam PA, Blüher M. Retinol-binding protein 4 in obesity and metabolic dysfunctions. Mol Cell Endocrinol. 2021; 531:111312.

36. Olsen T, Blomhoff R. Retinol, Retinoic acid, and retinol-binding protein 4 are differentially associated with cardiovascular disease, type 2 diabetes, and obesity: an overview of human studies. Adv Nutr. 2020;11(3):644–66.

37. Huang T, Tobias DK, Hruby A, Rifai N, Tworoger SS, Hu FB. An increase in dietary quality is associated with favorable plasma biomarkers of the brain-adipose axis in apparently healthy US women. J Nutr. 2016;146(3):1101–8.

38. Wang B, Pan Y, Yang G, Cui Z, Yu W, Liu H, Bai B. Sfrp5/Wnt5a and leptin/adiponectin signaling pathways are differentially associated with cardiovascular disease, type 2 diabetes, and chronic kidney disease. Lab Med. 2020;51(5):491–7.

39. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, Funahashi T, Yamauchi T, Funck-Brentano C, Kemel S, Cluzel P, Redheuil A, Davaine J, Maizy Z, Mentavari R, Bonnefont-Rousselot D, Gally P, Jaisson S, Vermeer C, Lacorte JM, Bousin N, Laroche S, Amouyal C, Hartemann A. Circulating Receptor Activator of Nuclear Factor kappaB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020; 19:140.

40. Spychalska-Zwolińska M, Anaszevicz M, Wiśniewska J, Mieczkowski A, Kowalczyk G, Banasi W, Czerniak B, Suppan K, Lis K, Zbikowska-Goźn M, Bartuzi Z, Budzyński J. Blood adipocytokine concentration in patients with peripheral arterial occlusive disease. Int Angiol. 2020; 39(6):500–508.

41. Kuźnicka M, Grodzicki T, Więcek A, Olszanecka-Glinianowicz M, Chudek J, Szuba B, Bożentowicz-Wikarek M, Brzozowska A, Zbylska A, Puzianowska-Kuźnicka M, Grodzicki T, Więcek A, Olssonecka-Glinianowicz M, Chudek J. Components of metabolic syndrome in relation to plasma levels of retinol binding protein 4 (RBP4) in a cohort of people aged 65 years and older. J Endocrinol Invest. 2018; 41:1211–1219.

42. Hajer GR, van der Graaf Y, Olihoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007; 154:750.e1–7.

43. Lai YH, Lin YL, Wang CH, Kuo CH, Hsu BG. Negative correlation of serum adiponectin level with peripheral artery occlusive disease in hemodialysis patients. Ci Ji Yi Xue Za Zhi. 2019; 32(1):70–74.

44. Kim-Mitsuyma S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yama-moto E, Sekigami T, Ogawa H, Matsui K. Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial. Sci Rep. 2019; 9(1):16589.

45. Bourron O, Phan F, Diallo MH, Hajage D, Aubert CE, Carlier A, Salem JE, Funck-Brentano C, Kemel S, Cluzel P, Redheuil A, Davaine J, Maizy Z, Mentavari R, Bonnefont-Rousselot D, Gally P, Jaisson S, Vermeer C, Lacorte JM, Bousin N, Laroche S, Amouyal C, Hartemann A. Circulating Receptor Activator of Nuclear Factor kappaB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020; 19:140.

46. Sitler-Maksymiuk K, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Chruściel P, Roman M, Chudzik A. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality in patients with type 2 diabetes. Cardiovasc Diabetol. 2016; 15:17.

47. Hajer GR, van der Graaf Y, Olihoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007; 154:750.e1–7.

48. Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteouros S, Blaha MJ, Martin SS, Rysz J, Toth PP, Lip GY, Pencina MJ, Ray KK, Baron M. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on plasma adiponectin concentrations: systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208.